Your browser doesn't support javascript.
Novel automated sample-to-result SARS-CoV-2 laboratory-developed RT-PCR assay for high-throughput testing using LabTurbo AIO 48 system.
Jian, Ming-Jr; Chung, Hsing-Yi; Chang, Chih-Kai; Lin, Jung-Chung; Yeh, Kuo-Ming; Chiu, Sheng-Kang; Wang, Yi-Hui; Liao, Shu-Jung; Li, Shih-Yi; Hsieh, Shan-Shan; Perng, Cherng-Lih; Chang, Feng-Yee; Shang, Hung-Sheng.
  • Jian MJ; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Chung HY; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Chang CK; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Lin JC; Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Yeh KM; Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Chiu SK; Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Wang YH; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Liao SJ; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Li SY; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Hsieh SS; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Perng CL; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China.
  • Chang FY; Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China. Electronic address: fychang@ndmctsgh.edu.tw.
  • Shang HS; Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China. Electronic address: iamkeith001@gmail.com.
Clin Chim Acta ; 514: 54-58, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-971428
ABSTRACT
BACKGROUND AND

AIMS:

Immediate detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for preventing the spread of coronavirus disease 2019 (COVID-19). The LabTurbo AIO 48 system is an automated platform that allows nucleic acid extraction and sample analysis on the same instrument, producing faster results without affecting their accuracy. We aimed to independently evaluate the LabTurbo AIO 48 (all-in-one system) for SARS-CoV-2 detection. MATERIALS AND

METHODS:

Comparative limit of detection (LOD) was assessed on both the LabTurbo AIO 48 and current standard detection system based on real-time reverse transcriptase polymerase chain reaction (RT-PCR), using SARS-CoV-2 RNA control. Additional 125 primary clinical samples were assessed using both the protocols in parallel.

RESULTS:

The turnaround time from sample to results for 48 samples analyzed on LabTurbo AIO 48 was approximately 2.5 h, whereas that analyzed using the in-house RT-PCR protocol was 4.8 h. LabTurbo AIO 48 also demonstrated higher sensitivity than our reference RT-PCR assay, with a LOD of 9.4 copies/reaction. The overall percentage agreement between both the methods for 125 samples was 100%.

CONCLUSION:

LabTurbo AIO 48 is a robust detection option for SARS-CoV-2, allowing faster results and, consequently, aiding in better control and prevention of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: High-Throughput Screening Assays / Real-Time Polymerase Chain Reaction / COVID-19 Testing Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Clin Chim Acta Year: 2021 Document Type: Article Affiliation country: J.cca.2020.12.003

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: High-Throughput Screening Assays / Real-Time Polymerase Chain Reaction / COVID-19 Testing Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Clin Chim Acta Year: 2021 Document Type: Article Affiliation country: J.cca.2020.12.003